2022
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2022, 66: 23-32. PMID: 36255460, DOI: 10.1007/s00125-022-05815-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSGLT2 inhibitorsDrug categoriesSodium-glucose cotransporter 2 inhibitorsCardio-renal benefitsNormal blood glucose concentrationsCotransporter 2 inhibitorsClasses of medicationsAnti-inflammatory effectsSerious adverse effectsType 1 diabetesBlood glucose levelsBlood glucose concentrationKidney outcomesRare complicationBlood pressureSGLT2 inhibitionGlucose levelsKetone levelsBody weightType 2Ketone bodiesAdverse effectsGlucose concentrationInhibitorsEdged sword
2020
120-LB: Small Molecule Activator of Pyruvate Kinase Regulates In Vivo Glucose Homeostasis
ABULIZI A, CARDONE R, SIEBEL S, KUNG C, KIBBEY R. 120-LB: Small Molecule Activator of Pyruvate Kinase Regulates In Vivo Glucose Homeostasis. Diabetes 2020, 69 DOI: 10.2337/db20-120-lb.Peer-Reviewed Original ResearchEndogenous glucose productionNonalcoholic fatty liver diseaseWhole-body insulin sensitivityHFD-fed ratsInsulin sensitivityAgios PharmaceuticalsRegular chowInsulin resistanceBody weightInsulin-stimulated peripheral glucose uptakeGlucose productionHigh-fat diet ratsHyperinsulinemic-euglycemic clamp studiesSmall molecule activatorsMuscle triglyceride contentSevere liver dysfunctionFatty liver diseasePeripheral insulin sensitivityAmerican Diabetes AssociationWhole-body energy expenditurePeripheral glucose uptakeHigh-fat dietType 2 diabetesFat diet ratsPotential therapeutic target